Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the new bull market shaping up right now, it likely has a good shot of actually delivering what analysts are hoping to see.
Does that mean this stock's ascent is inevitable in the near term? Or is Wall Street getting ahead of itself?
Let's start by examining the case in favor of Intellia performing as the analysts expect. Before the close of 2024, the biotech will have two ongoing phase 3 clinical programs that aim to therapeutically, and potentially permanently, correct the genes responsible for a pair of heritable rare illnesses, transthyretin (ATTR) amyloidosis, and hereditary angioedema (HAE).
Source Fool.com
Intellia Therapeutics Inc Aktie
Die Intellia Therapeutics Inc Aktie verzeichnet mehrere Buy-Einschätzungen, was auf eine positive Tendenz hindeutet.
Mit einem Kursziel von 60 € für Intellia Therapeutics Inc, würde dies eine mehr als zweifache Steigerung des aktuellen Kurses von 19.81 € bedeuten.
